<DOC>
	<DOCNO>NCT02069561</DOCNO>
	<brief_summary>The aim study test Eicosapentaenoic acid 's effect marker relevant colorectal carcinogenesis , RNA DNA profile , possibility Eicosapentaenoic Acid treatment might associate change gut microbiota metabolomic profile patient long-standing ulcerative colitis .</brief_summary>
	<brief_title>Effects Eicosapentaenoic Acid Subjects High Risk Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<criteria>Arm : experimental Patients ulcerative colitis ( diagnose base clinical criterion , endoscopic histological ) last 8 year , clinical activity ( SCCAI = 0 ) , stable treatment ( without change treatment previous 3 month ) mesalamine , immunomodulators / biologics . Baseline fecal calprotectin &gt; 150 microgram / g. Signed informed consent . Patients receive systemic steroid two month prior study entry . Patients take concomitant warfarin blood thinner . Known suspect hypersensitivity eicosapentaenoic acid/omega 3 . Women pregnant childbearing age accept use contraceptive method specify study ( oral contraception , IUDs ) breastfeed woman . Patients severe medical condition , opinion investigator , contraindicate patient 's participation study . Changes treatment / use experimental drug within 3 month inclusion study . Use Probiotics Arm : intervention Inclusion criterion Subjects undergo screen colonoscopy within regional colorectal cancer screen programme Signed informed consent Polypectomy biopsy forceps . Exclusion criterion HBVpositive , HCVpositive , HIVpositive otherwise affect infectious disease Subjects undergoing chemo radiation therapy within six month prior surgery Patients receive systemic steroid two month prior study entry Patients undergoing antibiotic therapy within three month prior study Patients treat probiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>